|Over a month ago|
Sernova initiated with a Buy at H.C. Wainwright » 06:0707/0507/05/22
H.C. Wainwright analyst…
H.C. Wainwright analyst Joseph Pantginis initiated coverage of Sernova with a Buy rating and C$6 price target. The analyst views the company as a "differentiated regenerative medicine play" and sees initial promise of its Cell Pouch system in Type 1 diabetes patients in driving insulin independence.